2024
CHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Jacobs J, Manning M, Reshef A, Yamagami K, Shetty H, Lawo J, Pollen M, Hsu F. CHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s30-s31. DOI: 10.1016/j.anai.2024.08.121.Peer-Reviewed Original ResearchInjection-site reactionsLong-term prophylaxisHereditary angioedemaReduce treatment burdenIncidence of injection-site reactionsInjection-site adverse eventsPhase 3 clinical programTreatment burdenInjection site-relatedPlacebo-receiving patientsPhase 3 studyStudy treatment groupsFavorable safety profileLife-threatening attacksTotal disease controlOnce-monthlySafety profileAdverse eventsPhase 3Clinical studiesPatient proportionErythemaPatientsMonoclonal antibodiesPruritus
2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. The Journal Of Allergy And Clinical Immunology In Practice 2016, 4: 497-504. PMID: 26895621, DOI: 10.1016/j.jaip.2015.12.019.Peer-Reviewed Original ResearchConceptsRapid drug desensitizationDrug desensitizationAllergic patientsLife expectancyMonoclonal antibodiesNonallergic control groupOptimal pharmacological agentsOverall health costsFirst-line therapyAdministration of carboplatinConnective tissue diseaseStandard of careIndividual patient reactionsDesensitized patientsNonallergic groupAllergic groupLine therapyRisk stratificationTissue diseaseHypersensitivity reactionsChronic diseasesOvarian cancerSevere reactionsNonsignificant increasePharmacological agents
2010
Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies
Banerji A, Brennan P, Hesterberg P, Oren E, Hsu F. Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies. 2010, 297-311. DOI: 10.1007/978-1-60327-951-2_19.ChaptersDrug hypersensitivity reactionsDrug desensitizationManagement of allergyChemotherapeutic agentsHypersensitivity reactionsMonoclonal antibodiesLife-threatening infectious diseaseDrug-allergic individualsIgE-mediated drug hypersensitivity reactionsMast cell degranulationImmunology specialistsDesensitization protocolRheumatologic diseasesIncremental dosesCautious administrationCell degranulationSensitized individualsInfectious diseasesSmall molecule therapeuticsAllergyDesensitizationNumerous cancersAntibodiesDiseaseDrugs